Yuanquan Yang

Yuanquan Yang's research focuses on genitourinary cancers—prostate, bladder/urothelial, and kidney (renal cell) cancers—with an emphasis on immunotherapy and clinical trials testing new drug combinations. Much of the work involves early-phase (Phase 1/1b/2/3) clinical trials evaluating checkpoint inhibitors, antibody-drug conjugates, and bispecific antibodies, alongside studies of immune cell infiltration and tumor genomics as biomarkers of treatment response. This work is aimed at improving and personalizing treatment strategies for patients with advanced or metastatic urologic cancers.

Publication output has grown substantially over the last decade, rising from just 1 paper in 2017 to 30 in 2025, with a particularly sharp increase in the last three years.

Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026